SPARC investigational drug shows promise in phase 3 trial for treating inflammation, pain related to ocular surgery
The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. SPARC said its investigational drug met pre-specified primary and secondary endpoints."SPARC reported positive top-line results from its phase 3...
Login or Register to read the full article
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. SPARC said its investigational drug met pre-specified primary and secondary endpoints.
"SPARC reported positive top-line results from its phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. The trial met its pre-specified primary and secondary objectives," the company said in a regulatory filing.
The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.
Shares of SPARC were trading 0.56 per cent higher at Rs 170.30 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd